<DOC>
	<DOCNO>NCT02440009</DOCNO>
	<brief_summary>The study evaluate addition itraconazole glucocorticoid management acute stag allergic bronchopulmonary aspergillosis ( ABPA ) . Half participant receive glucocorticoid half receive itraconazole glucocorticoid</brief_summary>
	<brief_title>A Randomized Trial Itraconazole Acute Stages Allergic Bronchopulmonary Aspergillosis</brief_title>
	<detailed_description>The management allergic bronchopulmonary aspergillosis ( ABPA ) include two important aspect namely institution immunosuppressive therapy form glucocorticoid control immunologic activity , close monitoring detection relapse . Another possible target use antifungal agent attenuate fungal burden secondary fungal colonization airway . Oral corticosteroid currently treatment choice ABPA associate bronchial asthma . They suppress immune hyperfunction also anti-inflammatory . Itraconazole , oral triazole relatively low toxicity , active Aspergillus spp . vitro vivo . The activity itraconazole Aspergillus spp . ketoconazole . The administration itraconazole eliminate Aspergillus airway theoretically reduce allergic response ABPA . We hypothesize itraconazole give acute stage ABPA decrease chance relapse progression glucocorticoid-dependent ABPA .</detailed_description>
	<mesh_term>Aspergillosis</mesh_term>
	<mesh_term>Pulmonary Aspergillosis</mesh_term>
	<mesh_term>Aspergillosis , Allergic Bronchopulmonary</mesh_term>
	<mesh_term>Glucocorticoids</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Itraconazole</mesh_term>
	<mesh_term>Hydroxyitraconazole</mesh_term>
	<criteria>Treatment naive patient allergic bronchopulmonary aspergillosis ( ABPA ) define presence following : asthma immediate cutaneous hyperreactivity Aspergillus skin test A.fumigatus specific IgE level &gt; 0.35 kUA/L elevate total IgE level &gt; 1000 IU/mL , two follow feature : presence precipitate antibody A.fumigatus serum fix transient radiographic pulmonary opacity total eosinophil count &gt; 1000/ÂµL bronchiectasis HRCT chest Intake systemic glucocorticoid three week precede six month Exposure azoles last six month Immunosuppressive state uncontrolled diabetes mellitus , chronic renal failure , chronic liver failure others Patient immunosuppressive drug Pregnancy Enrollment another trial ABPA Failure provide inform consent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>